Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Robert Garnick joins Peregrine

This article was originally published in Scrip

Executive Summary

Peregrine Pharmaceuticals (US) has named Dr Robert Garnick head of regulatory affairs. He will be responsible for overseeing Peregrine's interactions with the US FDA and global regulatory agencies, and will lead the development of regulatory strategies for advancing the company's monoclonal antibody-based treatments for cancer and infectious diseases. Dr Garnick was formerly senior vice-president of regulatory, quality and compliance at Genentech.

Topics

Related Companies

UsernamePublicRestriction

Register

SC005162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel